Huang Michael, Lucas Kenneth
Division of Pediatric Hematology/Oncology, Department of Pediatrics, H085, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State Hershey Children's Hospital, 500 University Drive, P.O. Box 850, Hershey, PA 17033-0850, USA.
Sarcoma. 2011;2011:863210. doi: 10.1155/2011/863210. Epub 2010 Dec 1.
Ewing sarcoma (ES) is the second most common type of primary bone malignancy in children and young adults. Survival rates for localized ES have improved to upwards of 70% with aggressive chemotherapy and local control. On the other hand, there has been little improvement in survival rates for patients with metastatic or recurrent ES. Herein we review the different current therapeutic approaches available, including the different upfront and salvage chemotherapy regimens, the role for stem cell transplantation, and potential use of immunotherapy.
尤因肉瘤（ES）是儿童和年轻成人中第二常见的原发性骨恶性肿瘤类型。通过积极的化疗和局部控制，局限性ES的生存率已提高到70%以上。另一方面，转移性或复发性ES患者的生存率几乎没有改善。在此，我们回顾了目前可用的不同治疗方法，包括不同的一线和挽救性化疗方案、干细胞移植的作用以及免疫疗法的潜在应用。
